Prediction of progression in 95 patients with HHV8+ MCD treated with rituximab
| Univariate analysis using baseline characteristics . | HR . | St err . | 95% CI . | P . |
|---|---|---|---|---|
| Sex (male) | 1.42 | 0.53 | 0.69-2.95 | .34 |
| Age ≥ 50 y | 1.13 | 0.39 | 0.57-2.23 | .72 |
| HIV positive | 0.42 | 0.16 | 0.21-.87 | .02 |
| Previous KS | 0.76 | 0.28 | 0.36-1.58 | .46 |
| Hb < 10 g/dL | 2.55 | 0.89 | 1.29-5.05 | .01 |
| Platelets < 150 × 109/L | 0.67 | 0.29 | 0.29-1.55 | .35 |
| Albumin < 30 g/L | 0.80 | 0.29 | 0.40-1.61 | .53 |
| Gammaglobulins > 25 g/L | 1.11 | 0.40 | 0.50-2.26 | .77 |
| CRP > 100 mg/L | 0.65 | 0.28 | 0.28-1.50 | .31 |
| HHV8 DNA > 5 logs per mL | 0.86 | 0.34 | 0.39-1.85 | .69 |
| Univariate analysis using baseline characteristics . | HR . | St err . | 95% CI . | P . |
|---|---|---|---|---|
| Sex (male) | 1.42 | 0.53 | 0.69-2.95 | .34 |
| Age ≥ 50 y | 1.13 | 0.39 | 0.57-2.23 | .72 |
| HIV positive | 0.42 | 0.16 | 0.21-.87 | .02 |
| Previous KS | 0.76 | 0.28 | 0.36-1.58 | .46 |
| Hb < 10 g/dL | 2.55 | 0.89 | 1.29-5.05 | .01 |
| Platelets < 150 × 109/L | 0.67 | 0.29 | 0.29-1.55 | .35 |
| Albumin < 30 g/L | 0.80 | 0.29 | 0.40-1.61 | .53 |
| Gammaglobulins > 25 g/L | 1.11 | 0.40 | 0.50-2.26 | .77 |
| CRP > 100 mg/L | 0.65 | 0.28 | 0.28-1.50 | .31 |
| HHV8 DNA > 5 logs per mL | 0.86 | 0.34 | 0.39-1.85 | .69 |
| Multivariate log-linear regression model . | HR . | St err . | 95% CI . | P . |
|---|---|---|---|---|
| HIV positive | 0.47 | 0.17 | 0.23-.97 | .04 |
| Hb < 10 g/dL | 2.44 | 0.85 | 1.23-4.83 | .01 |
| Multivariate log-linear regression model . | HR . | St err . | 95% CI . | P . |
|---|---|---|---|---|
| HIV positive | 0.47 | 0.17 | 0.23-.97 | .04 |
| Hb < 10 g/dL | 2.44 | 0.85 | 1.23-4.83 | .01 |
| Univariate analysis including 3 time-dependent covariates: CD19+B cells ≥ 1 ×106/L, CRP ≥ 20 mg/L, and HHV8 DNA ≥ 3 logs per ml . | HR . | St err . | 95% CI . | P . |
|---|---|---|---|---|
| Sex (male) | 1.37 | 0.51 | 0.66-2.85 | .40 |
| Age ≥ 50 y | 1.12 | 0.38 | 0.58-2.19 | .73 |
| HIV positive | 0.38 | 0.14 | 0.18-.78 | .01 |
| Previous KS | 0.68 | 0.26 | 0.32-1.44 | .31 |
| Hb < 10 g/dL | 1.2 | 0.55 | 0.49-2.92 | .69 |
| Platelets < 150 ×109/L | 1.56 | 0.63 | 0.71-3.45 | .27 |
| Albumin < 30 g/L | 3.8 | 2.8 | 0.90-16.09 | .07 |
| Gammaglobulins > 25 g/L | 2.46 | 0.86 | 1.25-4.91 | .01 |
| CD19+ B cells ≥ 1 ×106/L | 1.62 | 0.57 | 0.81-3.24 | .17 |
| CRP ≥20 mg/L | 3.39 | 1.2 | 1.70-6.77 | .001 |
| HHV8 DNA ≥3 logs per mL | 3.59 | 1.31 | 1.75-7.35 | .001 |
| Univariate analysis including 3 time-dependent covariates: CD19+B cells ≥ 1 ×106/L, CRP ≥ 20 mg/L, and HHV8 DNA ≥ 3 logs per ml . | HR . | St err . | 95% CI . | P . |
|---|---|---|---|---|
| Sex (male) | 1.37 | 0.51 | 0.66-2.85 | .40 |
| Age ≥ 50 y | 1.12 | 0.38 | 0.58-2.19 | .73 |
| HIV positive | 0.38 | 0.14 | 0.18-.78 | .01 |
| Previous KS | 0.68 | 0.26 | 0.32-1.44 | .31 |
| Hb < 10 g/dL | 1.2 | 0.55 | 0.49-2.92 | .69 |
| Platelets < 150 ×109/L | 1.56 | 0.63 | 0.71-3.45 | .27 |
| Albumin < 30 g/L | 3.8 | 2.8 | 0.90-16.09 | .07 |
| Gammaglobulins > 25 g/L | 2.46 | 0.86 | 1.25-4.91 | .01 |
| CD19+ B cells ≥ 1 ×106/L | 1.62 | 0.57 | 0.81-3.24 | .17 |
| CRP ≥20 mg/L | 3.39 | 1.2 | 1.70-6.77 | .001 |
| HHV8 DNA ≥3 logs per mL | 3.59 | 1.31 | 1.75-7.35 | .001 |
| Multivariate log-linear regression model . | HR . | St err . | 95% CI . | P . |
|---|---|---|---|---|
| HIV positive | 0.35 | 0.13 | 0.17-.72 | .001 |
| CRP ≥ 20 mg/L | 2.44 | 0.94 | 1.14-5.19 | .01 |
| HHV8 DNA ≥ 3 logs per mL | 2.73 | 1.1 | 1.24-6 | .01 |
| Multivariate log-linear regression model . | HR . | St err . | 95% CI . | P . |
|---|---|---|---|---|
| HIV positive | 0.35 | 0.13 | 0.17-.72 | .001 |
| CRP ≥ 20 mg/L | 2.44 | 0.94 | 1.14-5.19 | .01 |
| HHV8 DNA ≥ 3 logs per mL | 2.73 | 1.1 | 1.24-6 | .01 |
HR, hazard ratio; Hb, hemoglobin; St err, standard error.
Statistically significant values are indicated in bold.